Redirecting T lymphocyte specificity using T cell receptor genes.
Redirecting T cells by transferring T cell receptor (TCR) genes from tumor-associated antigen (TAA)-reactive T cell clones into human peripheral blood lymphocytes (PBL) has therapeutic potential for the treatment of diseases, including cancer. T cell specificity can be altered using retroviruses encoding TCRalpha and TCRbeta chain genes, or chimeric immunoglobulin (cIg) genes containing signaling domains of CD3 zeta or Fc epsilon RI-gamma. This review evaluates recent studies using TCRs and cIgs to redirect T cell specificity and discusses some of the technical and biological hurdles that need to be addressed before these approaches can be successfully used to treat patients.
Kaplan
Barbara L F
BL
Department of Surgery, University of Chicago, Chicago, Illinois 60637, USA.
Yu
David C
DC
Clay
Timothy M
TM
Nishimura
Michael I
MI
D006801:Humans; D019169:Jurkat Cells; D011948:Receptors, Antigen, T-Cell / Q000235:genetics*; D013601:T-Lymphocytes / Q000276:immunology*; D014162:Transfection
D011948:Receptors, Antigen, T-Cell